SkinBioTherapeutics plc announced that Professor Cath O'Neill has confirmed that she intends to stand down as Chief Scientific Officer (CSO) and move to a Scientific Adviser role so that she can return to full time academia, as Professor of Translational Dermatology at the University of Manchester. Since the Company was founded, Cath has combined her academic and corporate roles. The Directors have been aware of her eventual desire to return to full time academia for some time.

Cath will retain a close connection with the Company, not only as one of its original founders, but in the capacity as a scientific adviser. She will continue to provide support and guidance on areas such as the intellectual property behind her inventions (AxisBiotix, Skinbiotix) and strategic developments in the microbiome arena. She also retains a significant personal shareholding of 2.47%.

The Board has commenced the search for a new CSO.